South Korea · Delayed Price · Currency is KRW Yuyu Pharma Statistics
Total Valuation
Yuyu Pharma has a market cap or net worth of KRW 67.08 billion. The enterprise value is 80.94 billion.
| Market Cap | 67.08B |
| Enterprise Value | 80.94B |
Important Dates
The last earnings date was Friday, November 14, 2025.
| Earnings Date | Nov 14, 2025 |
| Ex-Dividend Date | Dec 29, 2025 |
Share Statistics
Yuyu Pharma has 15.75 million shares outstanding. The number of shares has increased by 9.19% in one year.
| Current Share Class | 15.75M |
| Shares Outstanding | 15.75M |
| Shares Change (YoY) | +9.19% |
| Shares Change (QoQ) | +27.27% |
| Owned by Insiders (%) | 35.96% |
| Owned by Institutions (%) | 0.04% |
| Float | 10.08M |
Valuation Ratios
The trailing PE ratio is 14.79.
| PE Ratio | 14.79 |
| Forward PE | n/a |
| PS Ratio | 0.48 |
| PB Ratio | 0.48 |
| P/TBV Ratio | 0.55 |
| P/FCF Ratio | 26.08 |
| P/OCF Ratio | 7.47 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 4.81, with an EV/FCF ratio of 31.46.
| EV / Earnings | 16.56 |
| EV / Sales | 0.58 |
| EV / EBITDA | 4.81 |
| EV / EBIT | 7.23 |
| EV / FCF | 31.46 |
Financial Position
The company has a current ratio of 1.77, with a Debt / Equity ratio of 0.21.
| Current Ratio | 1.77 |
| Quick Ratio | 0.92 |
| Debt / Equity | 0.21 |
| Debt / EBITDA | 1.75 |
| Debt / FCF | 11.25 |
| Interest Coverage | 4.03 |
Financial Efficiency
Return on equity (ROE) is 5.40% and return on invested capital (ROIC) is 4.06%.
| Return on Equity (ROE) | 5.40% |
| Return on Assets (ROA) | 3.37% |
| Return on Invested Capital (ROIC) | 4.06% |
| Return on Capital Employed (ROCE) | 7.37% |
| Revenue Per Employee | 549.26M |
| Profits Per Employee | 19.25M |
| Employee Count | 254 |
| Asset Turnover | 0.69 |
| Inventory Turnover | 2.00 |
Taxes
In the past 12 months, Yuyu Pharma has paid 136.43 million in taxes.
| Income Tax | 136.43M |
| Effective Tax Rate | 1.83% |
Stock Price Statistics
The stock price has decreased by -1.39% in the last 52 weeks. The beta is 0.26, so Yuyu Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.26 |
| 52-Week Price Change | -1.39% |
| 50-Day Moving Average | 4,225.40 |
| 200-Day Moving Average | 4,441.25 |
| Relative Strength Index (RSI) | 56.37 |
| Average Volume (20 Days) | 36,303 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Yuyu Pharma had revenue of KRW 139.51 billion and earned 4.89 billion in profits. Earnings per share was 288.04.
| Revenue | 139.51B |
| Gross Profit | 53.33B |
| Operating Income | 10.88B |
| Pretax Income | 7.44B |
| Net Income | 4.89B |
| EBITDA | 16.52B |
| EBIT | 10.88B |
| Earnings Per Share (EPS) | 288.04 |
Balance Sheet
The company has 28.67 billion in cash and 28.95 billion in debt, giving a net cash position of -286.01 million or -18.16 per share.
| Cash & Cash Equivalents | 28.67B |
| Total Debt | 28.95B |
| Net Cash | -286.01M |
| Net Cash Per Share | -18.16 |
| Equity (Book Value) | 139.10B |
| Book Value Per Share | 7,355.34 |
| Working Capital | 41.91B |
Cash Flow
In the last 12 months, operating cash flow was 8.98 billion and capital expenditures -6.41 billion, giving a free cash flow of 2.57 billion.
| Operating Cash Flow | 8.98B |
| Capital Expenditures | -6.41B |
| Free Cash Flow | 2.57B |
| FCF Per Share | 163.37 |
Margins
Gross margin is 38.23%, with operating and profit margins of 7.80% and 4.32%.
| Gross Margin | 38.23% |
| Operating Margin | 7.80% |
| Pretax Margin | 5.33% |
| Profit Margin | 4.32% |
| EBITDA Margin | 11.84% |
| EBIT Margin | 7.80% |
| FCF Margin | 1.84% |
Dividends & Yields
This stock pays an annual dividend of 100.00, which amounts to a dividend yield of 2.37%.
| Dividend Per Share | 100.00 |
| Dividend Yield | 2.37% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 31.97% |
| Buyback Yield | -9.19% |
| Shareholder Yield | -6.83% |
| Earnings Yield | 7.29% |
| FCF Yield | 3.84% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on March 30, 2021. It was a forward split with a ratio of 2.
| Last Split Date | Mar 30, 2021 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
Yuyu Pharma has an Altman Z-Score of 2.01 and a Piotroski F-Score of 8. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.01 |
| Piotroski F-Score | 8 |